Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy

• Published in: Haematologica (Roma) Vol. 109; no. 7; pp. 2186 - 2195
• Main Authors: Tun, Aung M, Wang, Yucai, Maliske, Seth, Micallef, Ivana, Inwards, David J, Habermann, Thomas M, Porrata, Luis, Paludo, Jonas, Bisneto, Jose Villasboas, Rosenthal, Allison, Kharfan-Dabaja, Mohamed A, Ansell, Stephen M, Nowakowski, Grzegorz S, Farooq, Umar, Johnston, Patrick B
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.07.2024; Ferrata Storti Foundation
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation - methods; Humans; Lymphoma, Large B-Cell, Diffuse - mortality; Lymphoma, Large B-Cell, Diffuse - therapy; Male; Middle Aged; Non-Hodgkin Lymphoma; Recurrence; Retrospective Studies; Salvage Therapy - methods; Transplantation, Autologous; Treatment Outcome; Young Adult
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2023.284704

Chimeric antigen receptor T-cell therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a role for salvage chemotherapy (ST) and autologous stem cell transplant (ASCT) in certain circumstances (e.g., lack of resources for chimeric antigen receptor T-cell therapy, chemosensitive relapses). We retrospectively studied 230 patients with refractory or early relapsed DLBCL who underwent ST and ASCT. The median line of ST was one (range, 1-3). Best response before ASCT was complete response in 106 (46%) and partial response in 124 (54%) patients. The median follow-up after ASCT was 89.4 months. The median progression-free (PFS) and overall survival (OS) were 16.1 and 43.3 months, respectively. Patients relapsing between 6 to 12 months after frontline therapy had a numerically better median PFS (29.6 months) and OS (88.5 months). Patients who required one line of ST, compared to those requiring more than one line, had a better median PFS (37.9 vs. 3.9 months; P=0.0005) and OS (68.3 vs. 12.0 months; P=0.0005). Patients who achieved complete response had a better median PFS (71.1 vs. 6.3 months; P<0.0001) and OS (110.3 vs. 18.9 months; P<0.0001) than those in partial response. Patients who achieved complete response after one line of ST had the most favorable median PFS (88.5 months) and OS (117.2 months). Post-ASCT survival outcomes of patients with refractory or early relapsed DLBCL appeared reasonable and were particularly favorable in those who required only one line of ST to achieve complete response before ASCT, highlighting the role of this procedure in select patients with chemosensitive disease.